Scholarlink

Background <p>Measles is a highly contagious viral disease that remains a significant public health issue worldwide. Two doses of measles-containing vaccines are required to prevent it effectively. Evidence is limited on measles containing vaccination second-dose (MCV2) in Ethiopia in general, and in Merhabete district in particular. Therefore, this study aimed to assess the uptake of MCV2 and associated factors among children aged 24–35 months in Merhabete district, Central Ethiopia.</p> Methods <p>A community-based cross-sectional study was conducted in Merhabete district, North Shoa zone, from June 1–30, 2022 on 732 children aged 24–35 months. The collected data was entered to EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable logistic regression models were used to identify factors associated with the uptake of MCV2. Adjusted odds ratios with 95%CI and <i>P</i> &lt; 0.05 were used to measure the strength of association and declare statistically significant factors, respectively.</p> Results <p>The uptake of MCV2 was 63.3% (CI: 60–67%). Knowledge of MCV2 schedule (AOR: 2.151, CI: 1.05, 4.40), institutional delivery (AOR: 3.50, CI: 1.58, 7.77), ≥ 4 antenatal care visits (AOR: 2.56, CI: 1.25, 5.23), availability of immunization card (AOR: 9.96, CI: 4.26, 23.30), and mother’s age between 25 and 34 years (AOR: 2.95, CI: 1.30, 6.72) were statistically significant factors for the uptake of MCV2.</p> Conclusion <p>The uptake of MCV2 in Merhabete District was lower than the measles elimination target. Number of antenatal visits 4 or more, place of delivery, knowledge of MCV2 schedule, immunization card availability, and maternal age were found to be statistically significant factors for the uptake of MCV2. Therefore, health decision makers better to strengthen periodic monitoring and evaluation of the implementation of the MCV2 delivery programs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Uptake of second dose measles containing vaccine and associated factors among children aged 24–35 months in central Ethiopia: a community based cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月21日

查看全文
  • Ababye Mulatu,
  • Yawkal Tsega,
  • Nigus Cherie,
  • Mulugeta Desalegn Kasaye,
  • Asnakew Molla Mekonen

摘要

Background

Measles is a highly contagious viral disease that remains a significant public health issue worldwide. Two doses of measles-containing vaccines are required to prevent it effectively. Evidence is limited on measles containing vaccination second-dose (MCV2) in Ethiopia in general, and in Merhabete district in particular. Therefore, this study aimed to assess the uptake of MCV2 and associated factors among children aged 24–35 months in Merhabete district, Central Ethiopia.

Methods

A community-based cross-sectional study was conducted in Merhabete district, North Shoa zone, from June 1–30, 2022 on 732 children aged 24–35 months. The collected data was entered to EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable logistic regression models were used to identify factors associated with the uptake of MCV2. Adjusted odds ratios with 95%CI and P < 0.05 were used to measure the strength of association and declare statistically significant factors, respectively.

Results

The uptake of MCV2 was 63.3% (CI: 60–67%). Knowledge of MCV2 schedule (AOR: 2.151, CI: 1.05, 4.40), institutional delivery (AOR: 3.50, CI: 1.58, 7.77), ≥ 4 antenatal care visits (AOR: 2.56, CI: 1.25, 5.23), availability of immunization card (AOR: 9.96, CI: 4.26, 23.30), and mother’s age between 25 and 34 years (AOR: 2.95, CI: 1.30, 6.72) were statistically significant factors for the uptake of MCV2.

Conclusion

The uptake of MCV2 in Merhabete District was lower than the measles elimination target. Number of antenatal visits 4 or more, place of delivery, knowledge of MCV2 schedule, immunization card availability, and maternal age were found to be statistically significant factors for the uptake of MCV2. Therefore, health decision makers better to strengthen periodic monitoring and evaluation of the implementation of the MCV2 delivery programs.